- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Role of Antibody-Drug Conjugates in Multiple Myeloma
Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs.
EP: 1.Unmet Needs and Emerging Therapeutic Advances in Multiple Myeloma
EP: 2.Challenges in the Management of Relapsed/Refractory Multiple Myeloma
EP: 3.Addressing Therapeutic Gaps in Multiple Myeloma with Bispecific Antibody Therapies
EP: 4.Bispecific Antibodies in Multiple Myeloma and Practical Definitions of Lines of Therapy
EP: 5.Mechanisms of Action of Bispecific Antibodies in Multiple Myeloma
EP: 6.Evaluating Clinical Trial Data and Real-World Evidence of Bispecific Antibodies in Multiple Myeloma
EP: 7.Bispecific Antibody Efficacy and Safety in Multiple Myeloma: Updates from ASH 2025
EP: 8.Clinical Insights on the Efficacy and Safety of Bispecific Antibodies in Multiple Myeloma
EP: 9.Exploring Combination Bispecific Strategies in Multiple Myeloma with Talquetamab and Teclistamab from RedirecTT-1 Trial
EP: 10.Opportunities for Earlier Initiation of Bispecific Therapies in Multiple Myeloma
EP: 11.Role of Antibody-Drug Conjugates in Multiple Myeloma
EP: 12.Safety Considerations and Practical Strategies for Using Bispecific Antibodies in Multiple Myeloma
In this episode, experts discuss the reemergence of the antibody-drug conjugate belantamab and how it fits into a treatment landscape now dominated by bispecific antibodies and cellular therapies. Panelists explain that belantamab may offer an important option for patients who lack equitable access to bispecific T-cell engagers or CAR T therapy, especially in community settings more familiar with antibody drug conjugates. They note ongoing questions about sequencing, emphasizing that diminished responses seen when CAR T follows prior BCMA bispecific exposure have not yet been observed with belantamab. Experts highlight belantamab’s potential as an off-the-shelf therapy that can serve as a bridge for patients unable to reach specialized centers. They also reference data from the DREAMM-7 study showing progression-free survival approaching 30 months, positioning belantamab as a meaningful alternative for certain patients.
